Clinical-stage biotech company Galapagos, which is based in Belgium, has announced positive results of a Phase II clinical trial for two oral drugs designed to treat the main mutations in cystic fibrosis (CF) patients, including F508del and G551D. AbbVie has been working in collaboration with Galapagos in order to further the development…
News
Cambridge, Massachusetts-based Vertex Pharmaceuticals Incorporated announced Monday that it has signed a letter of intent with the pan-Canadian Pricing Alliance (pCPA) to enable public reimbursement of Kalydeco (ivacaftor) drug therapy for treatment of eligible Canadians ages 6 and older with cystic fibrosis (CF) who have the G551D gene…
Last Wednesday, the 37th European Cystic Fibrosis Conference gathered leading CF caregivers and researchers in Gothenburg, Sweden. The four-day program included seminars, round table talks, Meet the Expert sessions, and a physiotherapy short course, in order to facilitate acquisition and distribution of new knowledge and research in…
A recent study published in the Iranian Journal of Pediatrics suggests that taking probiotics supplements can help improve quality of life for patients with cystic fibrosis (CF). Persons with CF (and many other disease conditions) frequently suffer from imbalanced intestinal microbiota ecosystems and suffer consequent dysregulated immune functionalities exacerbated…
At the 37th European Cystic Fibrosis Society Conference, held June 11-14 in Sweden, representatives from Vertex Pharmaceuticals Inc. presented data from multiple clinical trials evaluating Kalydeco (ivacaftor) in patients with cystic fibrosis due to various mutations. “Not only does KALYDECO lead to significant initial improvements,…
Young people who suffer from physical disabilities or illnesses, such as cystic fibrosis, don’t always receive all of the necessary care and support they need to make a transition to care services. These are the conclusions of a study from the English Care and Quality Commission that reviewed…
For the 27th year, Cystic Fibrosis Research Inc. will hold a national conference to raise awareness of the disease and advocate for continued research and drug development. “Changing the Faces of Cystic Fibrosis: Inspiring Hope” will take place in San Francisco from August 1st through the 3rd, with several presentations designed…
Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency in its Phase 4 clinical trial of Panzytrat® 25,000. Results show that patients taking Panzytrat had better control over their steatorrhea, or fecal fat content. The study was designed to…
After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives…
A number of factors influence the health-related quality of life of patients with cystic fibrosis. A new study in the Italian Journal of Pediatrics written by a collaboration of researchers…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.